Core Viewpoint - The announcement details a share reduction plan by a senior executive of Aorite Pharmaceutical Co., Ltd. due to personal financial needs, involving a maximum reduction of 62,500 shares, which is 0.02% of the total share capital [2][3]. Group 1: Executive Shareholding Information - As of the announcement date, the total number of shares for Aorite Pharmaceutical is 406,195,234, with the executive Zhao Zhenping holding 250,000 shares, representing 0.06% of the total share capital [2]. Group 2: Reduction Plan Details - The executive plans to reduce shares through centralized bidding within three months after the announcement, starting 15 trading days later, with a maximum of 62,500 shares to be sold [3]. - The reduction will not exceed 25% of the executive's total shareholding, and any changes in share capital due to dividends or other corporate actions will adjust the reduction quantity accordingly [3]. Group 3: Other Relevant Information - The executive has no concerted actions with other shareholders and has made prior commitments regarding shareholding and reduction methods [4][6]. - The company will monitor the reduction plan and comply with relevant regulations, ensuring timely disclosure of any developments [9][17].

Key Points - The company announced the interest payment schedule for its convertible bonds, "Aorite Convertible Bonds," with the interest payment date set for July 28, 2025 [1][6] - The interest accrual period for the bonds is from July 26, 2024, to July 25, 2025, with a coupon rate of 0.3% [3][5] - The bondholders will receive a total interest amount of RMB 0.3 per bond (before tax) for each bond with a face value of RMB 100 [3][5] - The tax on interest income for individual investors is set at 20%, resulting in a net payment of RMB 0.24 per bond after tax [5] - The bond's registration date for interest payment is July 25, 2025, and the ex-dividend date is July 28, 2025 [4][6] - The company has appointed China Securities Depository and Clearing Corporation Limited Shanghai Branch to handle the interest payment process [4][5]

Group 1 - The core viewpoint of the announcement is that the credit rating for the company's convertible bonds and the company itself remains unchanged at AA- with a stable outlook [1][2] - The previous credit rating for the convertible bonds was AA- and the company’s main credit rating was also AA- with a stable outlook [1] - The credit rating was conducted by China Chengxin International Credit Rating Co., Ltd. based on a comprehensive analysis of the company's operational status and industry conditions [2] Group 2 - The tracking credit rating report was issued on June 27, 2025, confirming that both the convertible bonds and the company maintain their AA- ratings [2] - The announcement emphasizes that there are no false records, misleading statements, or significant omissions in the content [1]

证券代码：605116 证券简称：奥锐特 公告编号：2025-044 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于因实施权益分派调整"奥锐转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 因实施 2024 年年度权益分派,本公司的相关证券停复牌情况如下： "奥锐转债" 自权益分派公告前一交易日（2025 年 6 月 12 日）至权益分派股权登记日（2025 年 6 月 19 日）期间停止转股，自 2025 年 6 月 20 日起恢复转股。 停牌起 停牌 | 证券代码 | 证券简称 | 停复牌类型 | | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | | | | 始日 | 期间 | | | 奥锐特药业股份有限公司（以下简称"公司"）于2024年7月26日向不特定对 象发行可转换公司债券812,120,000.00元，并于2024年8月15日起在上海证券交易 所上市交易，债券简称"奥锐转债"，债券代码"1110 ...

Summary of Key Points Core Viewpoint - The company has announced an adjustment to the total cash dividend distribution for the fiscal year 2024, reducing it from RMB 117,796,550.00 to RMB 117,401,979.77 due to changes in the number of shares eligible for profit distribution resulting from convertible bond conversions and share buybacks [1][3]. Group 1: Dividend Distribution Adjustment - The total cash dividend amount for 2024 is adjusted to RMB 117,401,979.77 (including tax), maintaining a distribution of RMB 2.90 per 10 shares [1][3]. - The adjustment is necessary due to changes in the total number of shares participating in the profit distribution caused by the conversion of convertible bonds and the company's share buyback program [1][2]. Group 2: Convertible Bonds and Share Buyback - The company has issued convertible bonds, with a conversion period from February 5, 2025, to July 25, 2030, and an initial conversion price of RMB 25.23 per share, resulting in an increase of 234 shares due to conversions [2]. - The company has repurchased a total of 1,360,900 shares since January 1, 2025, with 79 shares used for convertible bond conversions, leaving 1,360,821 shares in the repurchase account, which will not participate in the profit distribution [2].

Group 1 - The company will stop the conversion of its convertible bonds "Aorite Convertible Bonds" (bond code: 111021) from June 12, 2025, until the equity distribution registration date due to the 2024 annual equity distribution [1][2] - The company plans to distribute a cash dividend of 2.90 yuan (including tax) for every 10 shares to all shareholders, excluding treasury stock [1][2] - The company will adjust the conversion price of the convertible bonds according to the issuance terms and relevant regulations after the equity distribution [2] Group 2 - The company will announce the implementation of the equity distribution and the adjustment of the convertible bond conversion price on June 13, 2025 [2] - Holders of the convertible bonds can convert their bonds into shares until June 11, 2025, to enjoy the equity distribution [2] - The company will maintain the per-share distribution ratio unchanged, adjusting the total distribution amount if there are changes in the total share capital before the equity distribution registration date [1][2]

Group 1 - The company announced a share repurchase plan with a total expected amount between 60 million and 120 million RMB [1][2] - The repurchase will be conducted through centralized bidding and is intended for the conversion of the company's convertible bonds [1][2] - As of May 31, 2025, the company has repurchased a total of 1.3609 million shares, representing 0.34% of the total share capital, with a total expenditure of approximately 27.09 million RMB [2] Group 2 - The repurchase price ranged from 18.83 RMB to 21.00 RMB per share [1][2] - The board of directors approved the repurchase plan with unanimous consent during the twelfth board meeting [1] - The repurchase period is set to last for up to 12 months following the board's approval [1]

明天161124港股小盘LOF会封死跌停的，而且，后天还会封死跌停，我怀疑最后就是跌到成本附近，大家白忙活。 这让我想起个故事。 上次我去澡堂子洗澡： 牛：老板，你这儿洗澡多少钱？ 老板：男浴池10元，女浴池100元。 牛：为什么女浴池那么贵？ 老板：你就说想去男浴池还是女浴池？ 牛：一听这话，果断交了100块。 兴冲冲进女浴池一看，全是买票进来的男的。。。 被骗过一次长记性了。 但前天我去澡堂子，心里又痒痒了，我想虽然概率很低，但成本不高，万一要是能遇到个女的呢？ 最后还是忍不住买了100块钱的票。 风语转债：董事会提议下修 维尔转债：下修到底 赛力医疗：收到证监会湖北监管局行政处罚决定书 | 转债代码 | 转债名称 | 强赎天计数 | 现价 | 转股价值 | 溢价率 | 剩余规模 | 转债占正股 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | (亿元) | 流通市值比 | | 128144 | 利民转债 | 还需0天 | 145.777 | 146.35 | -0.39% | 5.042 | 11.10% | | 1136 ...

Core Viewpoint - The announcement details the change of the continuous supervision sponsor representative for Aorite Pharmaceutical Co., Ltd. due to the work change of the original representative, ensuring the orderly continuation of the supervision work [1][2]. Group 1: Change of Sponsor Representative - Aorite Pharmaceutical received a notice from Guotai Junan Securities regarding the replacement of the continuous supervision sponsor representative [1]. - The original representatives, Lin Zengjin and Wang Ziyang, were responsible for the supervision of the company's convertible bond issuance project, with Lin Zengjin being replaced by Pang Jun due to work changes [1][2]. - The new continuous supervision sponsor representatives for the 2024 convertible bond project are Wang Ziyang and Pang Jun [2]. Group 2: Convertible Bond Information - The company issued 812.12 million yuan worth of convertible bonds on July 26, 2024, with a maturity of six years and a face value of 100 yuan per bond [7]. - The initial conversion price for the bonds is set at 25.23 yuan per share, and the bonds can be converted into shares starting from February 5, 2025 [7]. - The bond's coupon rates increase progressively from 0.30% in the first year to 2.50% in the sixth year [7]. Group 3: Price Adjustment Conditions - The conditions for adjusting the conversion price are triggered if the company's stock price closes below 21.45 yuan (85% of the conversion price) for at least 15 out of 30 consecutive trading days [6][11]. - As of April 14, 2025, the stock price had already closed below the threshold for 10 trading days, indicating a potential for triggering the price adjustment [11]. - If the adjustment is triggered, the company will hold a board meeting to decide on the adjustment and will disclose the information accordingly [6][9].